Abstract
The phase 3 RESONANCE trial investigated the efficacy and safety of perioperative versus adjuvant S-1 plus oxaliplatin (SOX) chemotherapy for stage II/III resectable gastric cancer. In this randomized, open-label trial involving 756 patients in the modified intention-to-treat (mITT) population, perioperative chemotherapy (PC) significantly improved the three-year disease-free survival (DFS) rate (61.7% vs. 53.8%, p = 0.019) and the R0 resection rate (94.9% vs. 83.7%, p < 0.0001) compared to adjuvant chemotherapy (AC). Safety profiles were comparable between the two groups. These findings suggest that perioperative SOX is a superior approach for managing locally advanced gastric cancer.
Introduction
Treatment standards for locally advanced gastric cancer have historically differed by region. While Western guidelines favor perioperative chemotherapy, East Asian practice has traditionally centered on upfront surgery followed by adjuvant chemotherapy. The RESONANCE trial aimed to provide robust evidence for the use of perioperative SOX (S-1 plus oxaliplatin) in an Asian population, comparing it directly against the standard adjuvant approach.
Methods
This phase 3 trial enrolled 772 patients with stage II/III resectable gastric cancer across 19 centers in China. Patients were randomized to either:
- Perioperative Chemotherapy (PC): 2–4 cycles of SOX before surgery, followed by 4–6 cycles after surgery.
- Adjuvant Chemotherapy (AC): Upfront surgery followed by 8 cycles of SOX.
The primary endpoint was the three-year DFS rate in the mITT population (n=756).
Results
The trial met its primary endpoint, demonstrating a significant survival advantage for the perioperative approach. The three-year DFS rate was 61.7% in the PC arm compared to 53.8% in the AC arm (HR 0.76; 95% CI 0.61-0.96; p=0.019).
Subgroup analysis revealed that the benefit was most pronounced in patients with Stage III disease (HR 0.72, p=0.009), whereas the difference in Stage II patients did not reach statistical significance (p=0.272).
Beyond survival, the PC arm showed superior surgical outcomes. The R0 resection rate—indicating complete tumor removal with clear margins—was significantly higher in the PC group (94.9% vs. 83.7%, p < 0.0001). Additionally, 23.6% of patients in the PC arm achieved a pathological complete response (pCR), indicating the effectiveness of preoperative "downstaging."
Patient compliance was also notably higher in the perioperative group; 41.1% of PC patients completed all eight cycles of chemotherapy, compared to only 19.2% in the AC group. This suggests that chemotherapy is better tolerated when initiated before the physiological stress of major surgery.
Discussion and Conclusion
The RESONANCE trial provides strong evidence that perioperative SOX chemotherapy improves survival and surgical success for stage II/III gastric cancer. The "downstaging" effect of preoperative treatment likely facilitates more effective R0 resections. Furthermore, the improved compliance in the PC arm highlights a practical advantage of the perioperative sequence.
While the study is limited by potential staging inaccuracies and a lack of molecular biomarker data (e.g., MSI status), the results support a shift toward perioperative SOX as a standard of care for locally advanced gastric cancer in Asian clinical practice. Future research will likely explore the integration of immunotherapy into this perioperative framework.
Summary updated